Retrospective Cohort Study
Copyright ©The Author(s) 2019.
World J Gastrointest Oncol. Nov 15, 2019; 11(11): 1031-1042
Published online Nov 15, 2019. doi: 10.4251/wjgo.v11.i11.1031
Table 2 Baseline characteristics of eligible patients
Total (n = 95)Oral (n = 57)Infusional (n = 38)P value
Gender (%)
Male52 (54.7)32 (56.1)20 (52.6)0.900
Age (yr)
Median61.061.061.00.622
Age ≥ 70 (%)21 (22.1)12 (21.1)9 (23.7)0.960
ECOG performance status
07 (7.4)4 (7.0)3 (7.9)0.383
180 (84.2)50 (87.7)30 (78.9)
28 (8.4)3 (5.3)5 (13.2)
30 (0)0 (0)0 (0)
40 (0)0 (0)0 (0)
Site of primary tumor (%)
Right-sided colon20 (21.1)15 (26.3)5 (13.2)0.114
Left-sided colon49 (51.6)25 (43.9)24 (63.2)
Rectum22 (23.2)13 (22.8)9 (23.7)
Multiple4 (4.2)4 (7.0)0 (0.0)
Timing of metastasis (%)
Synchronous72 (75.8)40 (70.2)32 (84.2)0.187
Metachronous23 (24.2)17 (29.8)6 (15.8)
Extent of the disease (%)
Primary resected168 (71.6)42 (73.7)26 (68.4)0.745
Liver-only metastatsis44 (46.3)26 (45.6)18 (47.4)1.000
> 1 site of metastasis40 (42.1)24 (42.1)16 (42.1)1.000
Site of metastasis (%)
Liver67 (70.5)39 (68.4)28 (73.7)
Lymph Nodes28 (29.5)17 (29.8)11 (28.9)
Peritoneum21 (22.1)11 (19.3)10 (26.3)
Lung17 (17.9)11 (19.3)6 (15.8)
Bone3 (3.2)2 (3.5)1 (2.6)
Others8 (8.4)6 (10.5)2 (5.3)